FDA

Last week, we published part 1 of our digital health trends and predictions piece, covering big picture trends like vertical integration and healthcare consumerization, as well as some of the buzzy tech trends of voice, AI, and blockchain.

Nokia has announced that it will disable the pulse wave velocity measurement feature on its Withings’ Body Cardio scale as of January 24.

Last September, Tidepool — a diabetes data management platform — was among the nine companies chosen to participate in the FDA’s experimental pre-certification program pilot.

Updated with statement from Eli Lilly Indianapolis-based pharma company Eli Lilly recently recieved FDA 510K clearance for a new mobile app called Go Dose, a diabetes management and insulin dosing app for users of Humalog, Lilly's rapid-acting insulin.

Last November, as part of an investigative series on Apple's meetings with the FDA, we reported the company's stated plans to develop "two possible (and related) products in the cardiac space" which would require FDA clearance.

Health enterprise SaaS company Welltok announced an expanded partnership with IBM Watson Health.

IBM Watson Health has announced a joint initiative with the US Food and Drug Administration to study the use of blockchain technology to share health data to ultimately improve public health.

Over the past year, MobiHealthNews has covered 36 devices that received clearance from the Food and Drug Administration.

Over and above clearing a number of devices, the FDA had a busy year in 2016, passing a number of draft and final guidances related to digital health, having some notable conversations with vendors, and even turning down some devices whose FDA clearance was expected this year.

Neurometrix has received FDA clearance for a new smartphone-controlled version of Quell, its wearable for pain relief, the company announced last week.